Smruthi Organics Ltd. engages in the manufacture and sale of bulk drugs and drug intermediates. The company is headquartered in Solapur, Maharashtra and currently employs 308 full-time employees. The company went IPO on 2017-08-29. The Company’s operating segments include Formulation. The firm's products include AMLODIPINE BESILATE, AMISULPRIDE, CARBIDOPA, CIPROFLOXACIN, DILOXANIDE FUROATE, FENOFIBRATE, METFORMIN HYDROCHLORIDE, NORFLOXACIN, PEFLOXACIN, TELMISARTAN, AMLODIPINE BASE and PHTHALOYL AMLODIPINE. The firm has 2 manufacturing facilities in Solapur, Maharashtra. with a combined reactor capacity of over 320 kiloliters. The firm manufactures API from kilo to metric ton scale. The firm serves pharmaceutical companies in India and across the globe. The firm caters to both domestic and international markets.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.